EQ VS ORGS Stock Comparison

Performance

EQ
10/100

EQ returned -70.89% in the last 12 months. Based on SPY's performance of -16.09%, its performance is below average giving it a score of 10 of 100.

ORGS
10/100

ORGS returned -74.88% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

EQ
100/100

2 analysts offer 12-month price targets for EQ. Together, they have an average target of 0, the most optimistic target put EQ at 0 within 12-months and the most pessimistic has EQ at 0.

ORGS
75/100

1 analysts offer 12-month price targets for ORGS. Together, they have an average target of 0, the most optimistic target put ORGS at 0 within 12-months and the most pessimistic has ORGS at 0.

Sentiment

EQ
72/100

EQ had a bullish sentiment score of 71.71% across Twitter and StockTwits over the last 12 months. It had an average of 4.25 posts, 3.92 comments, and 7.17 likes per day.

ORGS

"Sentiment" not found for ORGS

Technicals

EQ
10/100

EQ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

ORGS
11/100

ORGS receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

EQ
10/100

EQ has missed earnings 8 times in the last 20 quarters.

ORGS
10/100

ORGS has missed earnings 7 times in the last 20 quarters.

Profit

EQ
10/100

Out of the last 20 quarters, EQ has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ORGS
13/100

Out of the last 20 quarters, ORGS has had 1 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

EQ
34/100

EQ has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

ORGS
50/100

ORGS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Equillium, Inc. Common Stock Summary

Nasdaq / EQ

Healthcare

Biotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Orgenesis Inc. Common Stock Summary

Nasdaq / ORGS

Healthcare

Biotechnology

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Power up your portfolio